PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

SUMMARY OF COLLECTION ASSEMBLYAs expected, the Pre-Clinical Collection is relatively small compared to the ClinicalCollection (Figure 13). Its relative contribution is highest at the early discovery stage, andlower later on. Typical drug development stages are noted on the chart at right. Atazanavirwas approved by the US FDA for HIV treatment in 2003. Note that after 2008 the data isincomplete because of publication lag.Figure 13. Invention Timelines vs Developmental Stages20
SECTION 5: GENERAL OVERVIEW OF THE COLLECTIONThe collection contains inventions that are very specific to Atazanavir and covercompositions, processes and methods of use directly involving the drug, but it also includescontextual inventions that allow inferences to be made about the use of drugs in HIVtreatment. For example, drug treatments may involve HIV-protease inhibitor drugs such asAtazanavir together with other anti-HIV treatments. Because of the issues of drugresistance in treatment of HIV infection or AIDS, it is standard practice to use coadministeredor combination drugs, and this is reflected in the collection. It is also apparentthat protease inhibitor drugs may have uses other than the treatment of HIV, and movementinto other therapeutic areas is also covered in the collection.Using this type of collection, the activity on Atazanavir can be examined either narrowly ormore expansively depending on the kind of insights being sought. In the analysis thatfollows, examples of both approaches will be provided, and Figure 13 is a case in point.The chart in Figure 14 shows the earliest priority year (closest to date of invention) forseveral different subsets of documents from the collection. The “all commercial” set coversthe majority of inventions in the collection except for those assigned to academic orgovernment institutions, or individual inventors. This is a broad point of view. The otherthree timelines (second axis) cover smaller subsets, i.e. the inventions specifically coveringHIV-protease inhibitor drugs (the drug class to which Atazanavir belongs), the inventionscovering HIV protease inhibitor drugs that contain a six-membered heterocyclic ringstructure (as Atazanavir does), and the inventions contributed to the field by academic andgovernment inventors. The early documents in this collection come from the commercialsector, with academia and government mostly involved later.Figure 14. Timelines for collection, including narrower subsets21
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21: CHEMICAL COLLECTIONThis is an examp
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

Create successful ePaper yourself

Delete template?

Save as template?